## Marianne T Severinsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7658079/publications.pdf

Version: 2024-02-01

91 papers 2,336 citations

23 h-index 252626 46 g-index

94 all docs 94 docs citations 94 times ranked 4292 citing authors

#	Article	IF	CITATIONS
1	Genomic profiling of a randomized trial of interferon-î± vs hydroxyurea in MPN reveals mutation-specific responses. Blood Advances, 2022, 6, 2107-2119.	2.5	26
2	A national Danish proof of concept on feasibility and safety of home -based intensive chemotherapy in patients with acute myeloid leukemia. Leukemia Research, 2022, 112, 106756.	0.4	3
3	A randomized trial of alendronate as prophylaxis against loss in bone mineral density following lymphoma treatment. Blood Advances, 2022, 6, 2549-2556.	2.5	4
4	Severity and 90-day survival of SARS-CoV-2 infection among patients with haematological disorders. Acta Oncol $\tilde{A}^3$ gica, 2022, 61, 500-504.	0.8	1
5	Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy. Blood Advances, 2022, 6, 2967-2976.	2.5	23
6	Patients in complete remission after R-CHOP(-like) therapy for diffuse large B-cell lymphoma have limited excess use of health care services in Denmark. Blood Cancer Journal, 2022, 12, 16.	2.8	3
7	Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial. BMC Cancer, 2022, 22, 147.	1.1	1
8	Validation of Postsurgical Venous Thromboembolism Diagnoses of Patients Undergoing Lower Limb Orthopedic Surgery in the Danish National Patient Registry. Clinical Epidemiology, 2022, Volume 14, 191-199.	1.5	2
9	Psychotropic Drug Use in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS): A Danish Nationwide Matched Cohort Study of 2404 AML and 1307 MDS Patients. Clinical Epidemiology, 2022, Volume 14, 225-237.	1.5	1
10	Mental health among patients with nonâ€Hodgkin lymphoma: A Danish nationwide study of psychotropic drug use in 8750 patients and 43 750 matched comparators. American Journal of Hematology, 2022, 97, 749-761.	2.0	6
11	Temporal changes in survival among adult patients with acute myeloid leukaemia in the period 2000–2016: a Danish populationâ€based study. British Journal of Haematology, 2021, 193, 482-487.	1.2	9
12	Venous thromboembolism after lower extremity orthopedic surgery: A populationâ€based nationwide cohort study. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 148-158.	1.0	9
13	SARSâ€CoVâ€2 infection among patients with haematological disorders: Severity and oneâ€month outcome in 66 Danish patients in a nationwide cohort study. European Journal of Haematology, 2021, 106, 72-81.	1.1	21
14	Treatment intensity and survival trends among real-world elderly AML patients diagnosed in the period 2001–2016: a Danish nationwide cohort study. Leukemia and Lymphoma, 2021, 62, 2014-2017.	0.6	3
15	A randomised evaluation of lowâ€dose cytosine arabinoside (ara ) plus tosedostat <i>versus</i> lowâ€dose ara  in older patients with acute myeloid leukaemia: results of the Llâ€1 trial. British Journal of Haematology, 2021, 194, 298-308.	1.2	6
16	The Danish Myelodysplastic Syndromes Database: Patient Characteristics and Validity of Data Records. Clinical Epidemiology, 2021, Volume 13, 439-451.	1.5	5
17	Parenthood Rates and Use of Assisted Reproductive Techniques in Younger Hodgkin Lymphoma Survivors: A Danish Population-Based Study. Journal of Clinical Oncology, 2021, 39, 3463-3472.	0.8	10
18	The prognostic impact of anthropometrics in acute myeloid leukemia treated with intensive chemotherapy $\hat{a} \in A$ Danish nationwide cohort study. Leukemia Research, 2021, 106, 106567.	0.4	2

#	Article	IF	CITATIONS
19	Direct costs of antineoplastic and supportive treatment for progressive multiple myeloma in a tax-based health system. Future Oncology, 2021, 17, 3331-3341.	1.1	O
20	Prothrombotic genotypes and risk of venous thromboembolism in occult cancer. Thrombosis Research, 2021, 205, 17-23.	0.8	4
21	Association of smoking and cancer with the risk of venous thromboembolism: the Scandinavian Thrombosis and Cancer cohort. Scientific Reports, 2021, 11, 18752.	1.6	6
22	Exhaled breath condensate in acute pulmonary embolism; a porcine study of effect of condensing temperature and feasibility of protein analysis by mass spectrometry. Journal of Breath Research, 2021, 15, 026005.	1.5	4
23	Patient-reported outcomes in patients with hematological relapse or progressive disease: a longitudinal observational study. Health and Quality of Life Outcomes, 2021, 19, 251.	1.0	1
24	Labor Market Attachment in Patients with Myeloproliferative Neoplasms: A Nationwide Matched Cohort Study. Blood, 2021, 138, 3627-3627.	0.6	O
25	Shared care follow-up of patients with B-cell neoplasms based on nurse-led telephone consultations and PRO-data: a feasibility study from the North Denmark Region. BMC Health Services Research, 2020, 20, 1047.	0.9	1
26	Introduction of a Comprehensive Diagnostic and Interdisciplinary Management Approach in Haematological Patients with Mucormycosis: A Pre and Post-Intervention Analysis. Journal of Fungi (Basel, Switzerland), 2020, 6, 268.	1.5	9
27	On estimating the time to statistical cure. BMC Medical Research Methodology, 2020, 20, 71.	1.4	12
28	Increased risk of osteoporosis following commonly used first-line treatments for lymphoma: a Danish Nationwide Cohort Study. Leukemia and Lymphoma, 2020, 61, 1345-1354.	0.6	16
29	Development of a Precision Medicine Workflow in Hematological Cancers, Aalborg University Hospital, Denmark. Cancers, 2020, 12, 312.	1.7	8
30	Normal myeloid progenitor cell subset-associated gene signatures for acute myeloid leukaemia subtyping with prognostic impact. PLoS ONE, 2020, 15, e0229593.	1.1	3
31	Epidemiology of Venous Thromboembolism After Second Cancer. Clinical Epidemiology, 2020, Volume 12, 377-386.	1.5	2
32	Depression and anxiety in Hodgkin lymphoma patients: A Danish nationwide cohort study of 945 patients. Cancer Medicine, 2020, 9, 4395-4404.	1.3	13
33	The prognostic effect of smoking status on intensively treated acute myeloid leukaemia – A Danish nationwide cohort study. British Journal of Haematology, 2020, 190, 236-243.	1.2	10
34	Robust Overall Survival and Sustained Efficacy Outcomes during Long Term Exposure to Momelotinib in JAK Inhibitor NaÃ-ve and Previously JAK Inhibitor Treated Intermediate/High Risk Myelofibrosis Patients. Blood, 2020, 136, 51-52.	0.6	12
35	Severe Peripheral Neuropathy From Treatment With Arsenic Trioxide in a Patient Suffering From Acute Promyelocytic Leukemia. Journal of Hematology (Brossard, Quebec), 2020, 9, 89-92.	0.4	4
36	Longer distance to specialized treatment centers does not adversely affect treatment intensity or outcomes in adult acute myeloid leukemia patients. A Danish national population-based cohort study. Clinical Epidemiology, 2019, Volume 11, 769-780.	1.5	4

#	Article	IF	CITATIONS
37	Socioeconomic impact of Hodgkin lymphoma in adult patients: a systematic literature review. Leukemia and Lymphoma, 2019, 60, 3116-3131.	0.6	13
38	No differential overall or relative survival effect of rituximab in male and female patients with diffuse large B-cell lymphoma: a Danish population-based study of 3783 patients. Leukemia and Lymphoma, 2019, 60, 2798-2801.	0.6	0
39	Addressing the room for improvement in management of acute promyelocytic leukemia. European Journal of Haematology, 2019, 102, 479-485.	1.1	5
40	Cancer Risk and Prognosis after a Hospital Contact for an Elevated Erythrocyte Sedimentation Rate. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 225-232.	1.1	6
41	Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response. Blood, 2019, 134, 4202-4202.	0.6	1
42	Fertility Rates in Young Hodgkin Lymphoma Survivors: A Danish Nationwide Cohort Study of 769 Patients. Blood, 2019, 134, 2841-2841.	0.6	O
43	Evolution of relative survival for acute promyelocytic leukemia patients alive at landmark time-points: a population-based study. Leukemia, 2018, 32, 2263-2303.	3.3	4
44	Autoimmune diseases, infections, use of antibiotics and the risk of acute myeloid leukaemia: a national populationâ€based caseâ€control study. British Journal of Haematology, 2018, 181, 205-214.	1.2	18
45	Associations between cohabitation status, treatment, and outcome in AML patients: a national population-based study. Blood, 2018, 131, 2730-2733.	0.6	5
46	Long-Term Incidence of Venous Thromboembolism in Cancer: The Scandinavian Thrombosis and Cancer Cohort. TH Open, 2018, 02, e131-e138.	0.7	4
47	Stringent or nonstringent complete remission and prognosis in acute myeloid leukemia: a Danish population-based study. Blood Advances, 2018, 2, 559-564.	2.5	8
48	NSAID consumption and risk of acute myeloid leukemia: a national population-based case-control study. Cancer Management and Research, 2018, Volume 10, 5043-5051.	0.9	1
49	Skewed ratio between type 1 and type 2 calreticulin mutations in essential thrombocytosis patients with concomitant Janus kinase 2 V617F mutation. Experimental Hematology, 2018, 68, 62-65.	0.2	7
50	Venous thromboembolism in chronic lymphocytic leukemia: a Danish nationwide cohort study. Blood Advances, 2018, 2, 3025-3034.	2.5	9
51	Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial. Blood, 2018, 132, 580-580.	0.6	14
52	From Mild Cytopenia to Overt MDS and AML, the Mutational Profile Predicts Progression, but Not Survival. Blood, 2018, 132, 794-794.	0.6	O
53	Molecular classification of tissue from a transformed non-Hogkinâ∈™s lymphoma case with unexpected long-time remission. Experimental Hematology and Oncology, 2017, 6, 3.	2.0	2
54	Anthropometrics and prognosis in diffuse large Bâ€eell lymphoma: a multicentre study of 653 patients. European Journal of Haematology, 2017, 98, 355-362.	1.1	2

#	Article	IF	Citations
55	The impact of initial cancer stage on the incidence of venous thromboembolism: the Scandinavian Thrombosis and Cancer (STAC) Cohort. Journal of Thrombosis and Haemostasis, 2017, 15, 1567-1575.	1.9	39
56	Epidemiology of venous thromboembolism in hematological cancers: The Scandinavian Thrombosis and Cancer (STAC) cohort. Thrombosis Research, 2017, 158, 157-160.	0.8	19
57	Association of Traditional Cardiovascular Risk Factors With Venous Thromboembolism. Circulation, 2017, 135, 7-16.	1.6	114
58	R-CHOP(-like) treatment of diffuse large B-cell lymphoma significantly reduces CT-assessed vertebral bone density: a single center study of 111 patients. Leukemia and Lymphoma, 2017, 58, 1105-1113.	0.6	26
59	Effects of Education and Income on Treatment and Outcome in Patients With Acute Myeloid Leukemia in a Tax-Supported Health Care System: A National Population-Based Cohort Study. Journal of Clinical Oncology, 2017, 35, 3678-3687.	0.8	30
60	The Danish National Acute Leukemia Registry. Clinical Epidemiology, 2016, Volume 8, 553-560.	1.5	26
61	OPTIC-2L: a Superiority Trial of Two Lower Doses of Ponatinib Versus Standard Dose Nilotinib in Second-Line Chronic Phase CML. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S60-S61.	0.2	2
62	Incidence of venous thromboembolism in patients with diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2016, 57, 2771-2776.	0.6	20
63	Improved outcome in acute myeloid leukemia patients enrolled in clinical trials: A national population-based cohort study of Danish intensive chemotherapy patients. Oncotarget, 2016, 7, 72044-72056.	0.8	18
64	Tumor suppressor microRNAs are downregulated in myelodysplastic syndrome with spliceosome mutations. Oncotarget, 2016, 7, 9951-9963.	0.8	27
65	Existing data sources in clinical epidemiology: the Scandinavian Thrombosis and Cancer Cohort. Clinical Epidemiology, 2015, 7, 401.	1.5	20
66	Comorbidity and performance status in acute myeloid leukemia patients: a nation-wide population-based cohort study. Leukemia, 2015, 29, 548-555.	3.3	57
67	Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study. Journal of Clinical Oncology, 2015, 33, 3641-3649.	0.8	340
68	No Development of Neutralizing Antibodies Against Recombinant Interferon-Alpha in Ph-Negative Myeloproliferative Neoplasms - a Prospective Study. Blood, 2015, 126, 5177-5177.	0.6	1
69	Response to Letter Regarding Article, "Impact of Incident Venous Thromboembolism on Risk of Arterial Thrombotic Diseases― Circulation, 2014, 130, e184-5.	1.6	1
70	Impact of Incident Venous Thromboembolism on Risk of Arterial Thrombotic Diseases. Circulation, 2014, 129, 855-863.	1.6	38
71	Fish intake and venous thromboembolism: A Danish follow-up study. Thrombosis Research, 2014, 133, 352-356.	0.8	10
72	Alcohol intake and risk of venous thromboembolism. Thrombosis and Haemostasis, 2013, 110, 39-45.	1.8	34

#	Article	IF	Citations
73	Single nucleotide polymorphisms and the risk of venous thrombosis: results from a Danish caseâ€cohort study. British Journal of Haematology, 2013, 160, 838-841.	1.2	26
74	Data quality in the Danish National Acute Leukemia Registry: a hematological data resource. Clinical Epidemiology, 2013, 5, 335.	1.5	48
75	Human MICL Is An Early Marker In Myeloid Differentiation and Identifies a Subgroup Of CML Patients With Expanded Granulocyte-Macrophage Progenitor Populations At Diagnosis. Blood, 2013, 122, 2704-2704.	0.6	0
76	Risk of arterial thrombosis in patients with primary chronic immune thrombocytopenia: a Danish populationâ€based cohort study. British Journal of Haematology, 2012, 159, 109-111.	1.2	45
77	High Early Death Rate with Excellent Survival Beyond Day 30 in Acute Promyelocytic Leukemia Confirmed in Unselected Patients: Results of a Population-Based Registry Study. Blood, 2012, 120, 3542-3542.	0.6	0
78	Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish populationâ€based cohort study. British Journal of Haematology, 2011, 152, 360-362.	1.2	113
79	Monoclonal gammopathy of undetermined significance and risk of venous thromboembolism. European Journal of Haematology, 2011, 86, 129-134.	1.1	29
80	Extramedullary Leukemia and Myeloid Sarcoma in AML: Results From a Population-Based Registry Study of 2261 Patients. Blood, 2011, 118, 2003-2003.	0.6	6
81	Anthropometric measures and epithelial ovarian cancer risk in the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2010, 126, 2404-2415.	2.3	68
82	Cigarette smoking, environmental tobacco smoke exposure and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2010, 126, 2394-2403.	2.3	118
83	Genetic susceptibility, smoking, obesity and risk of venous thromboembolism. British Journal of Haematology, 2010, 149, 273-279.	1.2	43
84	Venous thromboembolism discharge diagnoses in the Danish National Patient Registry should be used with caution. Journal of Clinical Epidemiology, 2010, 63, 223-228.	2.4	188
85	Body height and sex-related differences in incidence of venous thromboembolism: A Danish follow-up study. European Journal of Internal Medicine, 2010, 21, 268-272.	1.0	63
86	Survival of cancer patients with prior monoclonal gammopathy of undetermined significance. European Journal of Internal Medicine, 2010, 21, 564-568.	1.0	3
87	Anthropometry, Body Fat, and Venous Thromboembolism. Circulation, 2009, 120, 1850-1857.	1.6	120
88	Smoking and venous thromboembolism: a Danish follow-up study. Journal of Thrombosis and Haemostasis, 2009, 7, 1297-1303.	1.9	118
89	Body Size and Risk of Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 3252-3261.	1.1	104
90	Anthropometric characteristics and non-Hodgkin's lymphoma and multiple myeloma risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Haematologica, 2008, 93, 1666-1677.	1.7	78

#	Article	IF	CITATIONS
91	Risk of diabetes and the impact on preexisting diabetes in lymphoma patients treated with steroid-containing immunochemotherapy. Blood Advances, $0$ , , .	2.5	0